Exelixis (EXEL) Cash from Financing Activities (2010 - 2026)
Exelixis (EXEL) posted quarterly Cash from Financing Activities of -$457.1 million for Q2 2026, down 55.05% year-over-year from -$1.0 billion in Q2 2025, and down 79.56% quarter-over-quarter from -$254.6 million in Q1 2026.
Exelixis (EXEL) Cash from Financing Activities (2010 - 2026) Analysis & Trends
Exelixis' Cash from Financing Activities history runs 17 years deep, the most recent figure standing at -$457.1 million for Q2 2026.
- In Q2 2026, Cash from Financing Activities fell 55.05% year-over-year to -$457.1 million; the TTM figure through Apr 2026 stood at -$1.1 billion (down 53.04% YoY), while the FY2026 annual figure was -$969.6 million, down 54.2% from the prior year.
- Cash from Financing Activities for Q2 2026 stood at -$457.1 million, down from -$254.6 million in the prior quarter.
- The five-year high for Cash from Financing Activities was $5.7 million in Q3 2024, with the low at -$457.1 million in Q2 2026.
- The 5-year median for Cash from Financing Activities is -$184.0 million (2024), against an average of -$153.0 million.
- Peak annual rise in Cash from Financing Activities reached 2137.07% in 2023, while the deepest fall reached 10678.85% in 2023.
- Exelixis' Cash from Financing Activities stood at -$2.0 million in 2022, then slumped by 10193.21% to -$206.2 million in 2023, then jumped by 102.76% to $5.7 million in 2024, then sank by 1923.38% to -$103.9 million in 2025, then sank by 340.12% to -$457.1 million in 2026.
- Business Quant data shows EXEL's Cash from Financing Activities at -$457.1 million in Q2 2026, -$254.6 million in Q1 2026, and -$103.9 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.42 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -6.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -207,909.22 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -273.15 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 36.24 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 27.18 Mn |
| 10 | Exelixis | 12.75 Bn | 11.91 Bn | 608.03 Mn | -343.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 3, 2026 | -343.88 Mn |
| Jul 3, 2026 | -343.88 Mn |
| Apr 3, 2026 | -457.11 Mn |
| Apr 3, 2026 | -457.11 Mn |
| Jan 2, 2026 | -254.57 Mn |
| Jan 2, 2026 | -254.57 Mn |
| Oct 3, 2025 | -103.86 Mn |
| Oct 3, 2025 | -103.86 Mn |
| Jul 4, 2025 | -316.34 Mn |
| Jul 4, 2025 | -316.34 Mn |
| Apr 4, 2025 | -294.82 Mn |
| Apr 4, 2025 | -294.82 Mn |
| Jan 3, 2025 | -188.03 Mn |
| Jan 3, 2025 | -188.03 Mn |
| Sep 27, 2024 | 5.70 Mn |
| Sep 27, 2024 | 5.70 Mn |
| Jun 28, 2024 | -262.42 Mn |
| Jun 28, 2024 | -262.42 Mn |
| Mar 29, 2024 | -184.05 Mn |
| Mar 29, 2024 | -184.05 Mn |